솔이끼 추출물 또는 분획물을 포함하는 항염 또는 항암 조성물
    32.
    发明公开
    솔이끼 추출물 또는 분획물을 포함하는 항염 또는 항암 조성물 有权
    聚苯乙烯的乙醇提取物及其活性分解效应抗炎和抗炎药

    公开(公告)号:KR1020100055653A

    公开(公告)日:2010-05-27

    申请号:KR1020080114478

    申请日:2008-11-18

    Abstract: PURPOSE: An anti-inflammation or anti-cancer composition containing Polytrichum commune extract or fraction is provided to suppress NF-kappaB activation and to suppress expression of PGE2 gene. CONSTITUTION: An anti-inflammation or anti-cancer composition contains Polytrichum commune extract or fraction. A method for producing the Polytrichum commune extract comprises: a step of washing Polytrichum commune with distilled water at 100°C for 5 minutes to inactivate an enzyme; a step of pulverizing at 5,000rpm for 5minutes, 6,000rpm for 5 minutes, 7,000rpm for 20 minutes; and a step of centrifuging at 5,000xg for 30 minutes, and a step of drying supernatant. The Polytrichum commune fraction is a chloroform or butanol fraction.

    Abstract translation: 目的:提供含有Polytrichum commune提取物或级分的抗炎或抗癌组合物,以抑制NF-κB活化并抑制PGE2基因的表达。 构成:抗炎或抗癌组合物含有Polytrichum commune提取物或级分。 一种多菌属提取物的制造方法,其特征在于,在100℃下用蒸馏水洗涤Polytrichum commun 5分钟使酶失活的步骤; 以5,000rpm离心5分钟,6,000rpm 5分钟,7,000rpm搅拌20分钟的步骤; 以5000×g离心30分钟的步骤和上清液的干燥步骤。 Polytrichum commune级分是氯仿或丁醇级分。

    멜리틴 성분을 포함하는 간질환 치료용 약학조성물
    38.
    发明公开
    멜리틴 성분을 포함하는 간질환 치료용 약학조성물 无效
    包含梅毒素用于治疗肝病的药物组合物

    公开(公告)号:KR1020120125754A

    公开(公告)日:2012-11-19

    申请号:KR1020110043381

    申请日:2011-05-09

    CPC classification number: A61K9/19 A61K35/63 A61K38/17

    Abstract: PURPOSE: A pharmaceutical composition containing melitin ingredients is provided to treat liver diseases. CONSTITUTION: A pharmaceutical composition for treating liver diseases contains 0.001-0.05 wt% of melittin as an active ingredient. Mellitin is isolated from honey bee-derived bee venom. The composition additionally contains pharmaceutically acceptable carrier. Mellitin reduces inflammation-inducing cytokine expression in a liver tissue. The inflammation-inducing cytokine is TNF-alpha, IL-1beta, IL-6, or VCAM. [Reference numerals] (AA) Tumor necrosis factor(TNF-α); (BB) NC control group; (CC) TAA experimental group of liver cirrhosis; (DD) TAA + Mel experimental group of liver cirrhosis + melittin administration

    Abstract translation: 目的:提供含有melitin成分的药物组合物以治疗肝脏疾病。 构成:用于治疗肝病的药物组合物含有0.001-0.05重量%的蜂毒素作为活性成分。 蜜蜂蛋白是从蜜蜂衍生的蜂毒中分离出来的。 该组合物另外含有药学上可接受的载体。 Mellitin可以减少肝组织中炎症诱导的细胞因子表达。 炎性诱导细胞因子是TNF-α,IL-1β,IL-6或VCAM。 (AA)肿瘤坏死因子(TNF-α); (BB)NC对照组; (CC)TAA实验组肝硬化; (DD)TAA + Mel实验组肝硬化+蜂毒素给药

Patent Agency Ranking